SavedAdd your journal

Journals / Klinik Psikiyatri Dergisi / 2013 / Cilt: 16 - Sayı: 2

An Obsessive Compulsive Disorder Case Induced by Addition of Cefuroxime to Varenicline

Varenikline Sefuroksim Eklenmesiyle Gelişen Bir Obsesif Kompulsif Bozukluk Olgusu

ARDA KARAGÖL
ALİ ÇAYKÖYLÜ
Hatice KILIÇ
Yasemin EREN
Naci ÖZDEMİR
Pages
120–125
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We wanted to attract attentionto the importance of psychiatric evaluation before andafter the treatment, informing of patient about the possible psychiatric side effects and drug interaction

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Varenicline is the latest smoking cessation medicationapproved by Food and Drug Administration (FDA).
📊
Key Findings & Data:It ispartially agonistic to the ?4 ?2 subtype nicotinic acetylcholinergic receptors.
💡
Conclusion & Impact:We wanted to attract attentionto the importance of psychiatric evaluation before andafter the treatment, informing of patient about the possible psychiatric side effects and drug interaction
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Varenicline is the latest smoking cessation medicationapproved by Food and Drug Administration (FDA). It ispartially agonistic to the ?4 ?2 subtype nicotinic acetylcholinergic receptors. When varenicline is binded tothese receptors, it stimulates them with a lower activitythen nicotine (agonism). It also inhibits nicotines' activation on these receptors (antagonism). So thedopaminergic mezolymbic system can not be activated.Post marketing case reports, observations about vareniclin, caused some concerns about this pharmaceuticalspotential side effects. Varenicline may cause some psychiatric side effects. Cefuroxim is an antibiotic that canpass all the body fluids including serebro spinal fluid. Noneurological side effects noticed with cefoxitine exceptseizure which is very rarely seen. We presented anobsessive compulsive disorder which is induced by addition of cefuroxime to varenicline. It is possible thatvarenicline caused obsessive compulsive disorder by,activating nicotinergic type cholinergic receptors especially at amygdala and orbitofrontal cortex by partialagonism, dopaminergic stimulation, serotonergic reuptake inhibition by nicotinergic blockage and drug interaction with cefuroxime. We wanted to attract attentionto the importance of psychiatric evaluation before andafter the treatment, informing of patient about the possible psychiatric side effects and drug interaction

Özet

Vareniklin, gyda ilaç yönetimi (FDA) tarafyndan onaylanmy? en son sigara byraktyrma ilacydyr. ?4 ?2 alttipi nikotinik asetilkolinerjik reseptörlere parsiyel agonistik etkigösterir. Bu reseptörlere ba?lanan vareniklin, nikotindendaha dü?ük bir aktivite ile bu reseptörleri stimüle eder(agonizma). Ayryca nikotinin bu reseptörü stimüleetmesini de engeller (antagonizma). Dolayysyyla mezolimbik dopaminerjik sistem de stimüle edilemez. Vareniklin,pazara sürüldükten sonraki gözlemler ve olgu raporlarybu ilaçla ilgili potansiyel yan etkilerle ilgili kaygylaryn do?masyna neden olmu?tur. vareniklin, çe?itli psikiyatrik yanetkilere yol açabilmektedir. Sefuroksim, beyin omuriliksyvysy da dahil, tüm vücut syvylaryna da?ylan bir antibiyotiktir. Sefuroksim ile çok nadiren görülen "nöbet" dy?ynda nörolojik bir yan etki bildirilmemi?tir. Yazymyzda,varenikline sefuroksim eklenmesine ba?ly olarak geli?ti?idü?ünülen bir obsesif kompulsif bozukluk (OKB)olgusunu sunduk. Vareniklinin, özellikle amigdala veorbitofrontal korteksteki nikotinerjik tipteki kolinerjikreseptörleri dü?ük ?iddette ancak sürekli bir ?ekilde (parsiyel agonizma ile) uyarmasy dopaminerjik stimülasyonolu?turmasy, nikotinerjik blokaj ile serotoninin alynymynyazaltylmasy veya vareniklin ile sefuroksim arasyndaki ilaçetkile?imi OKB'yi tetiklemesi muhtemel mekanizmalardyr.Dolayysyyla vareniklin alan hastalarda tedaviye ba?lanmadan önce ve tedavinin devamynda yapylacak olanpsikiyatrik de?erlendirmenin ve hastayy bu olasy yan etkilerle ilgili olarak bilgilendirmenin ve ilaç etkile?imlerininönemine dikkat çekmek istedik

🔖

Cite This Article

KARAGÖL, A., ÇAYKÖYLÜ, A., KILIÇ, H., EREN, Y., ÖZDEMİR, N. (2013). An Obsessive Compulsive Disorder Case Induced by Addition of Cefuroxime to Varenicline. Klinik Psikiyatri Dergisi, Cilt: 16 - Sayı: 2, 120–125. https://ajindex.com/articles/205520

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Baxter LR, Phelps ME, Mazziotta JC ve ark.(1987) Local cere- bral glucose metabolic rates in obsessive- compulsive disorder: a comparison with rates in unipolar depression and normal nor- mal controls. Arch Gen Psychiatry, 44: 211-218.
  2. Baxter LR, Schwartz JM, Mazziotta JC ve ark. (1988) Cerebral glucose metabolic ratesin non depressed patients with obsessive compulsive disorder. Am J Psychiatry, 145:1560-1563.
  3. Breiter HC, Rauch SL, Kwong KK ve ark. (1996) Functional magnetic resonance imaging of symptom provocation in obses- sive-compulsive disorder. Arch Gen Psychiatry, 53: 595-606.
  4. Cardoner N, Harrison BJ, Pujol J ve ark. (2011) Enhanced brain responsiveness during active emotional face processing in obses- sive compulsive disorder, World J Biol Psychiatry, 12: 349-363.
  5. Carlsson ML (2000) On the role of cortical glutamate in obses- sive-compulsive disorder and attention-deficit hyperactivity dis- order, two phenomenologically antithetical conditions. Acta Psychiatr Scand, 102: 401-413. CHANTIX [Ylaç prospektüsü] (2006)
  6. New York, NY: Pfizer Inc. Coe JW, Brooks PR, Vetelino MG, ve ark. (2005) Varenicline: an ?4?2 nicotinic receptor partial agonist for smoking cessation. J Med Chem, 48:3474-3477.
  7. Cordero-Erausquin M, Marubio LM, Klink R, ve ark. (2000) Nicotinic receptor function: new perspectives from knockout mice. Trends Pharmacol Sci, 21:211-217.
  8. Del Casale A, Kotzalidis GD, Rapinesi C ve ark. (2011) Functional Neuroimaging in obsessive compulsive disorder, Neuropsychobiology, 64 (2): 61-85.
  9. Lucey JV, Butcher G, Clare AW ve ark. (1993) Elevated growth hormone responses to pyridostigmine in obsessive compulsive disorder: evidence of cholinergic supersensitivity. Am J Psychiatry, 150: 961-962.
  10. Lundberg S, Carlsson A, Norfeldt P ve ark. (2004) Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry, 28:1195-1199.
  11. Mc Clure JB, Swan GE, Jack L ve ark. (2009) Mood, side effects and smoking outcomes among persons with and without proba- ble lifetime depression taking varenicline, J Gen Int Medicine, 24:563-569.
  12. Moore TJ, Glenmullen J, Furberg CD (2010) Prescription drugs associated with reports of violence towards others, Plos one, 15:5. Nordahl TE, Benkelfat C, Semple WE ve ark. (1989) Cerebral glucose metabolic rates in obsessive-compulsive disorder.Neuropsychopharmacology, 2: 23-28.
  13. Obach RS, Reed Hagen AE ve ark. (2005) Metabolism and dis- position of varenicline, a selective alfa4 beta 2 acetylcholine receptor parti